Cancer, R&D

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

Sanofi’s pipeline remodeling program has claimed a pivotal combo approach to lung cancer along with a score of other terminations in Q4. And the moves underscore what’s hot — and not — in the oncology field.

Outlining the moves in their quarterly sit-down with analysts, Sanofi hit the kill switch on 13 development programs and 25 research projects. But the R&D group also hit the gas on 17 programs, about half of which are in oncology.

New R&D chief John Reed is pressing a strategy established by Elias Zerhouni, which involves more of an in-house focus, particularly in the wake of the recent Ablynx and Bioverativ buyouts, which added new research capabilities and drugs to the pipeline.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->